Interactions of nanoparticles with plasma proteins: Implication on clearance and toxicity of drug delivery systems

Expert Opinion on Drug Delivery

Volumn 8, Issue 3, 2011, Pages 343-357

  Karmali, Priya Prakash ^a   Simberg, Dmitri ^b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

clearance; nanoparticle; opsonization; toxicity

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BUCRILATE; CERULOPLASMIN; COLLOIDAL GOLD; COMPLEMENT COMPONENT C5 INHIBITOR; DAUNORUBICIN; DEXTRAN; DOXORUBICIN; HAPTOGLOBIN; IMMUNOGLOBULIN D; LIPOSOME; MYOGLOBIN; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PLASMA PROTEIN; PLASMINOGEN; POLY(N ISOPROPYLACRYLAMIDE); PROSTATE SPECIFIC ANTIGEN; RETINOL BINDING PROTEIN; SINGLE WALLED NANOTUBE; SUPERPARAMAGNETIC IRON OXIDE; THYROXINE BINDING GLOBULIN; TRANSFERRIN; TROPONIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN RECOGNITION; CELL INTERACTION; COMPLEMENT ACTIVATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; HUMAN; MACROPHAGE; MICELLE; NONHUMAN; OPSONIZATION; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN INTERACTION; REVIEW; SURFACE PROPERTY; UNSPECIFIED SIDE EFFECT;

BLOOD PROTEINS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PROTEIN BINDING;

EID: 79951898882     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.554818     Document Type: Review

References (122)

1. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964;8:660-8
2. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7(9):771-82
3. Park JH, von Maltzahn G, Ruoslahti E, et al. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed Engl 2008;47(38):7284-8
4. Cullis PR, Chonn A, Semple SC. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv Drug Deliv Rev 1998;32(1-2):3-17 (Pubitemid 28277172)
5. Radomski A, Jurasz P, Alonso-Escolano D, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol 2005;146(6):882-93 (Pubitemid 41622255)
6. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2(8):469-78 (Pubitemid 47220069)
7. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283-318 (Pubitemid 32476118)
8. Nemmar A, Hoylaerts MF, Hoet PH, et al. Ultrafine particles affect experimental thrombosis in an in vivo hamster model. Am J Respir Crit Care Med 2002;166(7):998-1004 (Pubitemid 35193233)
9. Perrault SD, Walkey C, Jennings T, et al. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 2009;9(5):1909-15
10. Simberg D, Duza T, Park JH, et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 2007;104(3):932-6 (Pubitemid 46154714)
11. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol 2008;26(10):552-8
12. Berry CC, Wells S, Charles S, et al. Cell response to dextran-derivatised iron oxide nanoparticles post internalisation. Biomaterials 2004;25(23):5405-13 (Pubitemid 38586755)
13. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005;113(7):823-39 (Pubitemid 40984181)
14. Aggarwal P, Hall JB, McLeland CB, et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009;61(6):428-37
15. Lynch I, Cedervall T, Lundqvist M, et al. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci 2007;134-135:167-74 (Pubitemid 47614904)
16. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216(2-3):106-21 (Pubitemid 41712000)
17. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3(4):311-26
18. Cedervall T, Lynch I, Foy M, et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl 2007;46(30):5754-6 (Pubitemid 47172204)
19. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997;7(6):1140-5 (Pubitemid 28372892)
20. Cedervall T, Lynch I, Lindman S, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 2007;104(7):2050-5 . An in-depth study of kinetics of plasma protein association with nanoparticles. (Pubitemid 46391350)
21. Walczyk D, Bombelli FB, Monopoli MP, et al. What the cell 'sees' in bionanoscience. J Am Chem Soc 2010;132(16):5761-8
22. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics 2002;2(1):3-10 (Pubitemid 34273093)
23. Gessner A, Lieske A, Paulke B, et al. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur J Pharm Biopharm 2002;54(2):165-70 (Pubitemid 34919390)
24. Chonn A, Semple SC, Cullis PR. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 1992;267(26):18759-65
25. Dobrovolskaia MA, Patri AK, Zheng J, et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 2008;5(3):106-17
26. Kim HR, Andrieux K, Delomenie C, et al. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis 2007;28(13):2252-61 (Pubitemid 47065153)
27. Gref R, Luck M, Quellec P, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 2000;18(3-4):301-13 (Pubitemid 30479870)
28. Shen Y, Jacobs JM, Camp DG II, et al. Ultra-high-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal Chem 2004;76(4):1134-44 (Pubitemid 38235564)
29. Simberg D, Park JH, Karmali PP, et al. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009;30(23-24):3926-33
30. Lynch I, Salvati A, Dawson KA. Protein-nanoparticle interactions: what does the cell see? Nat Nanotechnol 2009;4(9):546-7
31. Goppert TM, Muller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 2005;302(1-2):172-86 (Pubitemid 41242762)
32. Vroman L, Adams AL, Fischer GC, et al. Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 1980;55(1):156-9 (Pubitemid 10211912)
33. Nagayama S, Ogawara K, Fukuoka Y, et al. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm 2007;342(1-2):215-21 (Pubitemid 47259322)
34. Lacerda SH, Park JJ, Meuse C, et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 2010;4(1):365-79
35. Froehlich E, Mandeville JS, Jennings CJ, et al. Dendrimers bind human serum albumin. J Phys Chem B 2009;113(19):6986-93
36. Price ME, Cornelius RM, Brash JL. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim Biophys Acta 2001;1512(2):191-205 (Pubitemid 32530766)
37. Cornelius RM, Archambault J, Brash JL. Identification of apolipoprotein A-I as a major adsorbate on biomaterial surfaces after blood or plasma contact. Biomaterials 2002;23(17):3583-7 (Pubitemid 34626562)
38. Gessner A, Waicz R, Lieske A, et al. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm 2000;196(2):245-9 (Pubitemid 30105753)
39. Mattison KW, Dublin PL, Brittain IJ. Complex formation between bovine serum albumin and strong polyelectrolytes: effect of polymer charge density. J PhysChem 1998;102:3830-36 (Pubitemid 128584931)
40. Hattori T, Kimura K, Seyrek E, et al. Binding of bovine serum albumin to heparin determined by turbidimetric titration and frontal analysis continuous capillary electrophoresis. Anal Biochem 2001;295(2):168-67
41. Arima Y, Kawagoe M, Toda M, et al. Complement activation by polymers carrying hydroxyl groups. ACS Appl Mater Interfaces 2009;1(10):2400-7
42. Kuroki Y, Honma T, Chiba H, et al. A novel type of binding specificity to phospholipids for rat mannose-binding proteins isolated from serum and liver. FEBS Lett 1997;414(2):387-92 (Pubitemid 27389401)
43. Chacko BK, Appukuttan PS. Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera. Mol Immunol 2003;39(15):933-9 (Pubitemid 36419605)
44. Fujita T, Matsushita M, Endo Y. The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev 2004;198:185-202 (Pubitemid 38406944)
45. Moghimi SM, Patel HM. Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol-rich liposomes. FEBS Lett 1988;233(1):143-7
46. Kamps JA, Scherphof GL. Receptor versus non-receptor mediated clearance of liposomes. Adv Drug Deliv Rev 1998;32(1-2):81-97 (Pubitemid 28277177)
47. Bradley AJ, Devine DV, Ansell SM, et al. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch Biochem Biophys 1998;357(2):185-94 (Pubitemid 28419200)
48. Oku N, Tokudome Y, Namba Y, et al. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochim Biophys Acta 1996;1280(1):149-54 (Pubitemid 26108319)
49. Gessner A, Lieske A, Paulke BR, et al. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J Biomed Mater Res A 2003;65(3):319-26 (Pubitemid 37517267)
50. Pedersen MB, Zhou X, Larsen EK, et al. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J Immunol 2010;184(4):1931-45
51. Geys J, Nemmar A, Verbeken E, et al. Acute toxicity and prothrombotic effects of quantum dots: impact of surface charge. Environ Health Perspect 2008;116(12):1607-13
52. Taylor PR, Martinez-Pomares L, Stacey M, et al. Macrophage receptors and immune recognition. Annu Rev Immunol 2005;23:901-44 (Pubitemid 40563189)
53. Hsu MJ, Juliano RL. Interactions of liposomes with the reticuloendothelial system. II: nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim Biophys Acta 1982;720(4):411-19
54. Harashima H, Sakata K, Funato K, et al. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994;11(3):402-6 (Pubitemid 24117360)
55. Leroux JC, De Jaeghere F, Anner B, et al. An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D, L-lactic acid) nanoparticles by human monocytes. Life Sci 1995;57(7):695-703
56. Borchard G, Kreuter J. The role of serum complement on the organ distribution of intravenously administered poly (methyl methacrylate) nanoparticles: effects of pre-coating with plasma and with serum complement. Pharm Res 1996;13(7):1055-8 (Pubitemid 26259006)
57. Doran JE. A critical assessment of fibronectin's opsonic role for bacteria and microaggregates. Vox Sang 1983;45(5):337-48 (Pubitemid 14226963)
58. Falcone DJ. Fluorescent opsonization assay: binding of plasma fibronectin to fibrin-derivatized fluorescent particles does not enhance their uptake by macrophages. J Leukoc Biol 1986;39(1):1-12 (Pubitemid 16212680)
59. Kolb-Bachofen V. Uptake of toxic silica particles by isolated rat liver macrophages (Kupffer cells) is receptor mediated and can be blocked by competition. J Clin Invest 1992;90(5):1819-24
60. Williams KJ, Werth VP, Wolff JA. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect Biol Med 1984;27(3):417-31
61. Bisgaier CL, Siebenkas MV, Williams KJ. Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. J Biol Chem 1989;264(2):862-6 (Pubitemid 19038065)
62. Guo LS, Hamilton RL, Goerke J, et al. Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins. J Lipid Res 1980;21(8):993-1003
63. Kiwada H, Matsuo H, Harashima H. Identification of proteins mediating clearance of liposomes using a liver perfusion system. Adv Drug Deliv Rev 1998;32(1-2):61-79 (Pubitemid 28277176)
64. Chonn A, Semple SC, Cullis PR. Beta glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of 'non-self ' particles. J Biol Chem 1995;270(43):25845-9
65. Yan X, Kuipers F, Havekes LM, et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun 2005;328(1):57-62 (Pubitemid 40164635)
66. Yan X, Morselt HW, Scherphof GL, et al. The role of beta2-glycoprotein I in liposome-hepatocyte interaction. Biochim Biophys Acta 2004;1667(2):208-14
67. Schousboe I. beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985;66(5):1086-91 (Pubitemid 16250272)
68. Schreier H, Abra RM, Kaplan JE, et al. Murine plasma fibronectin depletion after intravenous injection of liposomes. Int J Pharm 1987;37(3):233-38 (Pubitemid 17088734)
69. Hong Y, Shaw PJ, Tattam BN, et al. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. Eur J Clin Pharmacol 2007;63(2):165-72 (Pubitemid 46147058)
70. Moghimi SM, Muir IS, Illum L, et al. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta 1993;1179(2):157-65 (Pubitemid 23328718)
71. Thiele L, Diederichs JE, Reszka R, et al. Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials 2003;24(8):1409-18 (Pubitemid 36069107)
72. Tandia BM, Vandenbranden M, Wattiez R, et al. Identification of human plasma proteins that bind to cationic lipid/DNA complex and analysis of their effects on transfection efficiency: implications for intravenous gene transfer. Mol Ther 2003;8(2):264-73 (Pubitemid 37062837)
73. Demoy M, Andreux JP, Weingarten C, et al. In vitro evaluation of nanoparticles spleen capture. Life Sci 1999;64(15):1329-37 (Pubitemid 29156861)
74. Kobzik L. Lung macrophage uptake of unopsonized environmental particulates. Role of scavenger-type receptors. J Immunol 1995;155(1):367-76
75. Furumoto K, Ogawara K, Nagayama S, et al. Important role of serum proteins associated on the surface of particles in their hepatic disposition. J Control Release 2002;83(1):89-96 (Pubitemid 35239817)
76. Le Cabec V, Emorine LJ, Toesca I, et al. The human macrophage mannose receptor is not a professional phagocytic receptor. J Leukoc Biol 2005;77(6):934-43 (Pubitemid 40770845)
77. Rappleye CA, Goldman WE. Fungal stealth technology. Trends Immunol 2008;29(1):18-24
78. Platt N, Gordon S. Scavenger receptors: diverse activities and promiscuous binding of polyanionic ligands. Chem Biol 1998;5(8):R193-203 (Pubitemid 28370172)
79. Greenwalt DE, Lipsky RH, Ockenhouse CF, et al. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood 1992;80(5):1105-15
80. Miyanishi M, Tada K, Koike M, et al. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007;450(7168):435-9 (Pubitemid 350126753)
81. Doi T, Higashino K, Kurihara Y, et al. Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptors. J Biol Chem 1993;268(3):2126-33 (Pubitemid 23033623)
82. Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol Sci 2009;110(1):138-55
83. Dutta D, Sundaram SK, Teeguarden JG, et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol Sci 2007;100(1):303-15 (Pubitemid 47617826)
84. Raynal I, Prigent P, Peyramaure S, et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004;39(1):56-63 (Pubitemid 38030177)
85. Nagayama S, Ogawara K, Minato K, et al. Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int J Pharm 2007;329(1-2):192-8 (Pubitemid 44937533)
86. Chung YI, Kim JC, Kim YH, et al. The effect of surface functionalization of PLGA nanoparticles by heparin- or chitosan-conjugated Pluronic on tumor targeting. J Control Release 2010;143(3):374-82
87. Oh KS, Song JY, Cho SH, et al. Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. J Control Release 2010;148(3):344-50
88. Hsu SH, Wen CJ, Al-Suwayeh SA, et al. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology 2010. [Epub ahead of print]
89. Esmaeili F, Ghahremani MH, Esmaeili B, et al. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm 2008;349(1-2):249-55 (Pubitemid 350299701)
90. Gaur U, Sahoo SK, De TK, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000;202(1-2):1-10 (Pubitemid 30466224)
91. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol 2002;9(Suppl 2):S304-6 (Pubitemid 34857701)
92. Torchilin VP, Trubetskoi VS. Which polymers can make nanoparticulate drug carriers longcirculating? Adv Drug Deliv Rev 1995;16:141-55
93. Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5(4):505-15
94. Dos Santos N, Allen C, Doppen AM, et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 2007;1768(6):1367-77 (Pubitemid 46782695)
95. Park JH, von Maltzahn G, Zhang L, et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small 2009;5(6):694-700
96. Needham D, McIntosh TJ, Lasic DD. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta 1992;1108(1):40-8
97. Nahrendorf M, Keliher E, Marinelli B, et al. Hybrid PET-optical imaging using targeted probes. Proc Natl Acad Sci USA 2010;107(17):7910-15
98. Choi CH, Alabi CA, Webster P, et al. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 2010;107(3):1235-40
99. Ishida T, Ichikawa T, Ichihara M, et al. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Control Release 2004;95(3):403-12 (Pubitemid 38340491)
100. Salvador-Morales C, Zhang L, Langer R, et al. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009;30(12):2231-40
101. Duncanson WJ, Figa MA, Hallock K, et al. Targeted binding of PLA microparticles with lipid-PEG-tethered ligands. Biomaterials 2007;28(33):4991-9 (Pubitemid 47362347)
102. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006;13(16):1222-34 (Pubitemid 44184716)
103. Andersen AJ, Hashemi SH, Andresen TL, et al. Complement: alive and kicking nanomedicines. J Biomed Nanotechnol 2009;5(4):364-72
104. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90(4):300-6 (Pubitemid 28182386)
105. Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14(9):1430-7 (Pubitemid 37185291)
106. Eckardt JR, Campbell E, Burris HA, et al. A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol 1994;17(6):498-501 (Pubitemid 24379353)
107. Agemy L, Sugahara KN, Kotamraju VR, et al. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 2010;116(15):2847-56
108. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004;25(26):5681-703 (Pubitemid 38624449)
109. Rausch K, Reuter A, Fischer K, et al. Evaluation of nanoparticle aggregation in human blood serum. Biomacromolecules 2010;11(11):2836-9
110. Moghimi SM, Porter CJ, Muir IS, et al. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem Biophys Res Commun 1991;177(2):861-6
111. Moghimi SM, Hedeman H, Muir IS, et al. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta 1993;1157(3):233-40 (Pubitemid 23207804)
112. Liu J, Zeng F, Allen C. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent. J Control Release 2005;103(2):481-97 (Pubitemid 40342543)
113. Simberg D, Weisman S, Talmon Y, et al. The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J Biol Chem 2003;278(41):39858-65 (Pubitemid 37248548)
114. Moret I, Esteban Peris J, Guillem VM, et al. Stability of PEI-DNA and DOTAP-DNA complexes: effect of alkaline pH, heparin and serum. J Control Release 2001;76(1-2):169-81 (Pubitemid 32786894)
115. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9(3):491-8
116. Nicolazzi C, Mignet N, de la Figuera N, et al. Anionic polyethyleneglycol lipids added to cationic lipoplexes increase their plasmatic circulation time. J Control Release 2003;88(3):429-43 (Pubitemid 36335802)
117. Mizuarai S, Ono K, You J, et al. Protamine-modified DDAB lipid vesicles promote gene transfer in the presence of serum. J Biochem (Tokyo) 2001;129(1):125-32 (Pubitemid 32150489)
118. Klajnert B, Pikala S, Bryszewska M. Haemolytic activity of polyamidoamine dendrimers and the protective role of human serum albumin. P Roy Soc A Math Phys 2010;466(2117):1527-34
119. Han MH, Chen J, Wang J, et al. Blood compatibility of polyamidoamine dendrimers and erythrocyte protection. J Biomed Nanotechnol 2010;6(1):82-92
120. Deng ZJ, Mortimer G, Schiller T, et al. Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology 2009;20(45):455101
121. Labarre D, Vauthier C, Chauvierre C, et al. Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 2005;26(24):5075-84 (Pubitemid 40354240)
122. Ameller T, Marsaud V, Legrand P, et al. Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties. Pharm Res 2003;20(7):1063-70 (Pubitemid 36774278)